Valaris Limited Common Shares vs GeneDx Holdings Corp — how do they compare? Valaris Limited Common Shares trades at $84.6 (market cap $5.88B), while GeneDx Holdings Corp trades at $68.61 (market cap $2.04B). The key difference: Valaris Limited Common Shares is far larger — about 2.9× GeneDx Holdings Corp's market cap, and Valaris Limited Common Shares is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Valaris Limited Common Shares for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| VAL | WGS | |
|---|---|---|
Market Cap | $5.88B | $2.04B |
Volume | 1,857,693 | 962,082 |
Sector | Energy | Health |
52-Week High | $113.42 | $167.51 |
52-Week Low | $48.15 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $6.51B | $2.08B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings (WGS) trades at $64.96, up 1.79% today, showing mixed technical signals with a bearish moving average trend but bullish oscillators. Fundamentally, the company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows a net loss of -$106M. Recent news highlights product launches and CEO recognition, while analyst sentiment remains strongly positive with 91% buy ratings.
The outlook for WGS is cautiously optimistic with strong analyst support and operational improvements, but significant risks persist including negative profitability margins and high valuation multiples. The consensus price target of $81 suggests 25% upside potential, though investors should monitor cash flow trends and competitive pressures in the genomics diagnostics space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Valaris Limited provides offshore contract drilling services to the oil and gas industry, operating a fleet of drillships, semisubmersibles, and jackup rigs across multiple regions worldwide.
Read more on VAL →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →